| External factors: | PCO-rHDL |
| Aging type: | Prevent |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Aging |
| Experiment: | SA-β-gal activity assay |
| Description: | However, PCO in solvent dose-dependently inhibited cellular senescence up to 65% and 70% at 9 and 46 ?M (final), respectively, along with an increase in cell number, suggesting that PCO had anti-senescent and cell proliferation effects (photos c and d). Moreover, PCO-rHDL showed a stronger anti-aging effect and greater cellular proliferation in a dose-dependent manner. Compared to the PBS control, PCO-rHDL-treated cells (photos f and g) showed 68% and 80% reduction of SA-β-gal positive cells, whereas rHDL-treated cells (photo e) showed 52% reduction. PCO-rHDL also showed a cell proliferation effect of up to 1.9-fold and 1.6-fold for (1:5)-rHDL and (1:1)-rHDL, respectively, compared to rHDL alone (photo e). |
| Regulatory pathway: | -- |
| R-EF-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation: